BACKGROUND: In this study we investigated whether the presence of p53 antibodies in sera before of during/after radiation therapy can predict increased survival in patients with non-small cell lung cancer. PATIENTS AND MATERIALS: Sera from 67 patients with a histopathologically confirmed diagnosis of nonsmall cell lung cancer have been investigated using sandwich ELISA (Dianova, Hamburg, Germany). Sera was collected before or during/after radiation therapy. RESULTS: Antibodies were detected in 18 (27%) patients. 46/67 (69%) of the sera had been taken before start of radiation therapy and the presence of p53 antibodies was a statistically significantly good prognostic factor in terms of increased survival (p = 0.025). CONCLUSION: p53 antibodies in sera, before the start of radiation therapy, can predict increased survival after radiation treatment in patients with non-small cell lung cancer.
BACKGROUND: In this study we investigated whether the presence of p53 antibodies in sera before of during/after radiation therapy can predict increased survival in patients with non-small cell lung cancer. PATIENTS AND MATERIALS: Sera from 67 patients with a histopathologically confirmed diagnosis of nonsmall cell lung cancer have been investigated using sandwich ELISA (Dianova, Hamburg, Germany). Sera was collected before or during/after radiation therapy. RESULTS: Antibodies were detected in 18 (27%) patients. 46/67 (69%) of the sera had been taken before start of radiation therapy and the presence of p53 antibodies was a statistically significantly good prognostic factor in terms of increased survival (p = 0.025). CONCLUSION:p53 antibodies in sera, before the start of radiation therapy, can predict increased survival after radiation treatment in patients with non-small cell lung cancer.
Authors: Nancy J Nesslinger; Alvin Ng; Kwong-Yok Tsang; Theresa Ferrara; Jeffrey Schlom; James L Gulley; Brad H Nelson Journal: Clin Cancer Res Date: 2010-06-18 Impact factor: 12.531
Authors: Michael Bergqvist; Daniel Brattström; Kristina Lamberg; Patrik Hesselius; Johan Wernlund; Anders Larsson; Gunnar Wagenius Journal: Neoplasia Date: 2003 Jul-Aug Impact factor: 5.715
Authors: D Brattström; M Bergqvist; K Lamberg; W Kraaz; L Scheibenflug; G Gustafsson; M Inganäs; G Wagenius; O Brodin Journal: Med Oncol Date: 1998-12 Impact factor: 3.064
Authors: P V Murray; T Soussi; M E O'Brien; I E Smith; S Brossault; A Norton; S Ashley; M Tavassoli Journal: Br J Cancer Date: 2000-12 Impact factor: 7.640
Authors: Michael Bergqvist; Daniel Brattström; Anders Larsson; Patrik Hesselius; Ola Brodin; Gunnar Wagenius Journal: BMC Cancer Date: 2004-09-14 Impact factor: 4.430